Literature DB >> 21848879

Tapered oral dexamethasone for the acute chest syndrome of sickle cell disease.

Charles T Quinn1, Marie J Stuart, Karen Kesler, Kenneth I Ataga, Winfred C Wang, Lori Styles, Kim Smith-Whitley, Ted Wun, Ashok Raj, Lewis L Hsu, Suba Krishnan, Frans A Kuypers, Yamaja Setty, Seungshin Rhee, Nigel S Key, George R Buchanan.   

Abstract

Tapered oral dexamethasone for acute chest syndrome (ACS) in sickle cell anaemia was studied using a novel ACS assessment tool and investigational biomarkers. Twelve participants were randomized (mean age 17·3 years) before early study termination. Dexamethasone decreased duration of hospitalization for ACS by 20·8 h compared to placebo (P = 0·024). Rebound pain occurred in both groups (3 dexamethasone versus 1 placebo). Overall, dexamethasone decreased the leucocyte activation biomarker, sL-selectin; however, participants with rebound pain had higher sL-selectin within 24 h of treatment (dexamethasone or placebo). This ACS assessment tool was feasibly applied, and sL-selectin is a promising biomarker of ACS therapy.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21848879      PMCID： PMC3368951          DOI： 10.1111/j.1365-2141.2011.08827.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


  15 in total

1.  Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease.

Authors:  N S Key; A Slungaard; L Dandelet; S C Nelson; C Moertel; L A Styles; F A Kuypers; R R Bach
Journal:  Blood       Date:  1998-06-01       Impact factor: 22.113

2.  Mechanisms of suppression of inducible nitric-oxide synthase (iNOS) expression in interferon (IFN)-gamma-stimulated RAW 264.7 cells by dexamethasone. Evidence for glucocorticoid-induced degradation of iNOS protein by calpain as a key step in post-transcriptional regulation.

Authors:  G Walker; J Pfeilschifter; D Kunz
Journal:  J Biol Chem       Date:  1997-06-27       Impact factor: 5.157

3.  Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.

Authors:  S J Pocock; R Simon
Journal:  Biometrics       Date:  1975-03       Impact factor: 2.571

4.  A treatment allocation procedure for sequential clinical trials.

Authors:  C B Begg; B Iglewicz
Journal:  Biometrics       Date:  1980-03       Impact factor: 2.571

5.  Acute chest syndrome in sickle cell disease: clinical presentation and course. Cooperative Study of Sickle Cell Disease.

Authors:  E P Vichinsky; L A Styles; L H Colangelo; E C Wright; O Castro; B Nickerson
Journal:  Blood       Date:  1997-03-01       Impact factor: 22.113

6.  Sickle cell acute chest syndrome: pathogenesis and rationale for treatment.

Authors:  M J Stuart; B N Setty
Journal:  Blood       Date:  1999-09-01       Impact factor: 22.113

7.  High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease.

Authors:  T C Griffin; D McIntire; G R Buchanan
Journal:  N Engl J Med       Date:  1994-03-17       Impact factor: 91.245

8.  Increased levels of the inflammatory biomarker C-reactive protein at baseline are associated with childhood sickle cell vasocclusive crises.

Authors:  Suba Krishnan; Yamaja Setty; Suhita G Betal; Vaidyula Vijender; Koneti Rao; Carlton Dampier; Marie Stuart
Journal:  Br J Haematol       Date:  2009-12-08       Impact factor: 6.998

9.  Beneficial effect of intravenous dexamethasone in children with mild to moderately severe acute chest syndrome complicating sickle cell disease.

Authors:  J C Bernini; Z R Rogers; E S Sandler; J S Reisch; C T Quinn; G R Buchanan
Journal:  Blood       Date:  1998-11-01       Impact factor: 22.113

10.  Hypoxaemia in sickle cell disease: biomarker modulation and relevance to pathophysiology.

Authors:  B N Yamaja Setty; Marie J Stuart; Carlton Dampier; Darcy Brodecki; Julian L Allen
Journal:  Lancet       Date:  2003-11-01       Impact factor: 79.321
View more
  16 in total

Review 1.  Advances in sickle cell therapies in the hydroxyurea era.

Authors:  Joshua J Field; David G Nathan
Journal:  Mol Med       Date:  2014-12-16       Impact factor: 6.354

2.  Intravenous magnesium for pediatric sickle cell vaso-occlusive crisis: methodological issues of a randomized controlled trial.

Authors:  Oluwakemi Badaki-Makun; J Paul Scott; Julie A Panepinto; T Charles Casper; Cheryl A Hillery; J Michael Dean; David C Brousseau
Journal:  Pediatr Blood Cancer       Date:  2014-01-17       Impact factor: 3.167

3.  Exploring barriers and facilitators to clinical trial enrollment in the context of sickle cell anemia and hydroxyurea.

Authors:  Jeffrey D Lebensburger; Robert F Sidonio; Michael R Debaun; Monika M Safford; Thomas H Howard; Isabel C Scarinci
Journal:  Pediatr Blood Cancer       Date:  2013-02-15       Impact factor: 3.167

4.  Simulation of various randomization strategies for a clinical trial in sickle cell disease.

Authors:  William J Meurer; Jason T Connor; Jeffrey Glassberg
Journal:  Hematology       Date:  2016-03-16       Impact factor: 2.269

5.  End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings.

Authors:  Ann T Farrell; Julie Panepinto; Ankit A Desai; Adetola A Kassim; Jeffrey Lebensburger; Mark C Walters; Daniel E Bauer; Rae M Blaylark; Donna M DiMichele; Mark T Gladwin; Nancy S Green; Kathryn Hassell; Gregory J Kato; Elizabeth S Klings; Donald B Kohn; Lakshmanan Krishnamurti; Jane Little; Julie Makani; Punam Malik; Patrick T McGann; Caterina Minniti; Claudia R Morris; Isaac Odame; Patricia Ann Oneal; Rosanna Setse; Poornima Sharma; Shalini Shenoy
Journal:  Blood Adv       Date:  2019-12-10

Review 6.  Systematic review of interventional sickle cell trials registered in ClinicalTrials.gov.

Authors:  Jeffrey D Lebensburger; Lee M Hilliard; Lauren E Pair; Robert Oster; Thomas H Howard; Gary R Cutter
Journal:  Clin Trials       Date:  2015-06-17       Impact factor: 2.486

Review 7.  Sickle cell disease in childhood: from newborn screening through transition to adult medical care.

Authors:  Charles T Quinn
Journal:  Pediatr Clin North Am       Date:  2013-12       Impact factor: 3.278

Review 8.  Inflammatory targets of therapy in sickle cell disease.

Authors:  Amma Owusu-Ansah; Chibueze A Ihunnah; Aisha L Walker; Solomon F Ofori-Acquah
Journal:  Transl Res       Date:  2015-07-11       Impact factor: 7.012

9.  Application of phospho-CyTOF to characterize immune activation in patients with sickle cell disease in an ex vivo model of thrombosis.

Authors:  Jeffrey Glassberg; Adeeb H Rahman; Mohammad Zafar; Caroline Cromwell; Alexa Punzalan; Juan Jose Badimon; Louis Aledort
Journal:  J Immunol Methods       Date:  2017-07-29       Impact factor: 2.303

10.  Advances in new drug therapies for the management of sickle cell disease.

Authors:  Kenneth I Ataga; Payal C Desai
Journal:  Expert Opin Orphan Drugs       Date:  2018-05-14       Impact factor: 0.694
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.